MA24569A1 - Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer - Google Patents

Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer

Info

Publication number
MA24569A1
MA24569A1 MA25114A MA25114A MA24569A1 MA 24569 A1 MA24569 A1 MA 24569A1 MA 25114 A MA25114 A MA 25114A MA 25114 A MA25114 A MA 25114A MA 24569 A1 MA24569 A1 MA 24569A1
Authority
MA
Morocco
Prior art keywords
inhibitors
farnesyl
hmg
coa
cancer
Prior art date
Application number
MA25114A
Other languages
English (en)
Inventor
Mohamed Kajiji Shama
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA24569A1 publication Critical patent/MA24569A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25114A 1997-06-16 1998-06-15 Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer MA24569A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
MA24569A1 true MA24569A1 (fr) 1998-12-31

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25114A MA24569A1 (fr) 1997-06-16 1998-06-15 Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (fr)
JP (1) JP3713051B2 (fr)
KR (1) KR100392573B1 (fr)
CN (1) CN1259868A (fr)
AP (1) AP9801261A0 (fr)
AR (1) AR013090A1 (fr)
AT (1) ATE235905T1 (fr)
BG (1) BG103946A (fr)
BR (1) BR9810616A (fr)
CA (1) CA2294399C (fr)
CO (1) CO4950607A1 (fr)
DE (1) DE69812933T2 (fr)
DK (1) DK0986387T3 (fr)
DZ (1) DZ2518A1 (fr)
EA (1) EA199901043A1 (fr)
ES (1) ES2196559T3 (fr)
GT (1) GT199800081A (fr)
HN (1) HN1998000091A (fr)
HR (1) HRP980328B1 (fr)
HU (1) HUP0004624A3 (fr)
ID (1) ID23014A (fr)
IL (1) IL132765A0 (fr)
IS (1) IS5259A (fr)
MA (1) MA24569A1 (fr)
NO (1) NO996206L (fr)
NZ (1) NZ500662A (fr)
OA (1) OA11231A (fr)
PA (1) PA8453601A1 (fr)
PE (1) PE82899A1 (fr)
PL (1) PL337651A1 (fr)
PT (1) PT986387E (fr)
SK (1) SK169699A3 (fr)
TN (1) TNSN98088A1 (fr)
TR (1) TR199903074T2 (fr)
UA (1) UA57081C2 (fr)
WO (1) WO1998057633A1 (fr)
ZA (1) ZA985182B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK16742000A3 (sk) 1998-05-12 2001-07-10 Warner-Lambert Company Kombinácie proteínovej farnesyltransferázy a inhibítorov hmg coa reduktázy a ich použitie pri liečbe rakoviny
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (fr) 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (fr) 2000-12-19 2010-12-21 Pfizer Products Inc. Formes cristallines de sels de 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinoleine-2-one, 2,3-dihydroxybutanedioate et procede de preparation
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
EP1555021A1 (fr) * 2004-01-16 2005-07-20 National Health Research Institutes Combinaisons d'un inhibiteur de la voie du mévalonate et d'un agoniste PPAR-gamma pour le traitement du cancer
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids

Also Published As

Publication number Publication date
ID23014A (id) 1999-12-30
HUP0004624A2 (hu) 2001-10-28
ES2196559T3 (es) 2003-12-16
AU7445998A (en) 1999-01-04
PA8453601A1 (es) 2000-05-24
DK0986387T3 (da) 2003-07-14
JP3713051B2 (ja) 2005-11-02
BG103946A (bg) 2000-07-31
TNSN98088A1 (fr) 2005-03-15
PE82899A1 (es) 1999-08-26
CO4950607A1 (es) 2000-09-01
IS5259A (is) 1999-11-19
UA57081C2 (uk) 2003-06-16
NO996206L (no) 2000-02-15
HRP980328B1 (en) 2002-06-30
DZ2518A1 (fr) 2003-02-01
HRP980328A2 (en) 1999-04-30
PL337651A1 (en) 2000-08-28
AU724676B2 (en) 2000-09-28
AR013090A1 (es) 2000-12-13
EP0986387A1 (fr) 2000-03-22
AP9801261A0 (en) 1999-12-11
WO1998057633A1 (fr) 1998-12-23
CA2294399C (fr) 2004-03-16
CN1259868A (zh) 2000-07-12
NZ500662A (en) 2001-10-26
KR100392573B1 (ko) 2003-07-23
DE69812933D1 (de) 2003-05-08
EA199901043A1 (ru) 2000-06-26
NO996206D0 (no) 1999-12-15
EP0986387B1 (fr) 2003-04-02
GT199800081A (es) 1999-12-07
KR20010013839A (ko) 2001-02-26
ZA985182B (en) 1999-12-17
CA2294399A1 (fr) 1998-12-23
HN1998000091A (es) 1999-09-29
DE69812933T2 (de) 2003-11-06
HUP0004624A3 (en) 2002-11-28
BR9810616A (pt) 2000-09-12
OA11231A (en) 2003-05-26
TR199903074T2 (xx) 2000-05-22
ATE235905T1 (de) 2003-04-15
PT986387E (pt) 2003-06-30
JP2000513031A (ja) 2000-10-03
IL132765A0 (en) 2001-03-19
SK169699A3 (en) 2000-06-12

Similar Documents

Publication Publication Date Title
FI972205A0 (fi) cGmp-PDE:n estäjiä erektiohäiriön hoidossa
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
NO986052L (no) Anticonvulsivt virkende sulfamatderivater for anvendelse ved behandling av fedme
FI20031516A7 (fi) Indolokarbatsolijohdannaisten käyttö eturauhasen patologisten tilojen hoidossa
DE69624812D1 (de) Verringerung des mehrwegeffekts in gps-empfängern
IL142908A0 (en) Compounds useful in the treatment of inflammatory diseases
DE69838374D1 (de) Prozessor und Verfahren zum Verringern von dessen Energieverbrauch
FR08C0013I2 (fr) Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer
EP0926955A4 (fr) Conjugues utiles dans le traitement du cancer de la prostate
MA24569A1 (fr) Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
NZ307958A (en) Benzisoxazole and indazole derivatives as long acting antipsychotic agents and particularly in the treatment of schizophrenia
AU9226198A (en) The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury
DE19580644D2 (de) Einrichtung zum feinblasigen Eintrag von Gasen in Flüssigkeit
EP1161255A4 (fr) Procedes et compositions pour le traitement de la dyserection
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
EP1298216A4 (fr) Procede pour traitement avec une enzyme
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
DE69713442D1 (de) Thioürazil-Derivate und diese enthaltende Metall-Oberflächebehandlungsmittel
TR199501530A1 (tr) Osteoporoz tedavisinde terapötik döngüde kullanim icin kit.
EP1019529A4 (fr) Procede pour le traitement du cancer
FI971994A7 (fi) Aryylioksisykloalkenyyli- ja aryylioksi-iminosykloalkenyylihydroksiureat 5-lipoksygenaasin inhibiittoreina
FR2747298B1 (fr) Le decortiqueur pour la consommation de crustaces